| Nov 12 |
TransCode Therapeutics Open Letter to Shareholders
|
| Nov 5 |
TransCode Therapeutics gets Nasdaq extension to regain compliance
|
| Nov 5 |
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
|
| Oct 23 |
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
|
| Oct 10 |
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
|
| Sep 17 |
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
|
| Sep 5 |
TransCode Therapeutics secures $2M grant for lead candidate
|
| Sep 5 |
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
|
| Aug 15 |
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
|
| Jul 29 |
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
|
